An Imaging Biomarker of Tumor-Infiltrating Lymphocytes to Risk-Stratify Patients With HPV-Associated Oropharyngeal Cancer.
Journal
Journal of the National Cancer Institute
ISSN: 1460-2105
Titre abrégé: J Natl Cancer Inst
Pays: United States
ID NLM: 7503089
Informations de publication
Date de publication:
11 04 2022
11 04 2022
Historique:
received:
18
05
2021
revised:
03
08
2021
accepted:
19
11
2021
pubmed:
2
12
2021
medline:
14
4
2022
entrez:
1
12
2021
Statut:
ppublish
Résumé
Human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) has excellent control rates compared to nonvirally associated OPSCC. Multiple trials are actively testing whether de-escalation of treatment intensity for these patients can maintain oncologic equipoise while reducing treatment-related toxicity. We have developed OP-TIL, a biomarker that characterizes the spatial interplay between tumor-infiltrating lymphocytes (TILs) and surrounding cells in histology images. Herein, we sought to test whether OP-TIL can segregate stage I HPV-associated OPSCC patients into low-risk and high-risk groups and aid in patient selection for de-escalation clinical trials. Association between OP-TIL and patient outcome was explored on whole slide hematoxylin and eosin images from 439 stage I HPV-associated OPSCC patients across 6 institutional cohorts. One institutional cohort (n = 94) was used to identify the most prognostic features and train a Cox regression model to predict risk of recurrence and death. Survival analysis was used to validate the algorithm as a biomarker of recurrence or death in the remaining 5 cohorts (n = 345). All statistical tests were 2-sided. OP-TIL separated stage I HPV-associated OPSCC patients with 30 or less pack-year smoking history into low-risk (2-year disease-free survival [DFS] = 94.2%; 5-year DFS = 88.4%) and high-risk (2-year DFS = 82.5%; 5-year DFS = 74.2%) groups (hazard ratio = 2.56, 95% confidence interval = 1.52 to 4.32; P < .001), even after adjusting for age, smoking status, T and N classification, and treatment modality on multivariate analysis for DFS (hazard ratio = 2.27, 95% confidence interval = 1.32 to 3.94; P = .003). OP-TIL can identify stage I HPV-associated OPSCC patients likely to be poor candidates for treatment de-escalation. Following validation on previously completed multi-institutional clinical trials, OP-TIL has the potential to be a biomarker, beyond clinical stage and HPV status, that can be used clinically to optimize patient selection for de-escalation.
Sections du résumé
BACKGROUND
Human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC) has excellent control rates compared to nonvirally associated OPSCC. Multiple trials are actively testing whether de-escalation of treatment intensity for these patients can maintain oncologic equipoise while reducing treatment-related toxicity. We have developed OP-TIL, a biomarker that characterizes the spatial interplay between tumor-infiltrating lymphocytes (TILs) and surrounding cells in histology images. Herein, we sought to test whether OP-TIL can segregate stage I HPV-associated OPSCC patients into low-risk and high-risk groups and aid in patient selection for de-escalation clinical trials.
METHODS
Association between OP-TIL and patient outcome was explored on whole slide hematoxylin and eosin images from 439 stage I HPV-associated OPSCC patients across 6 institutional cohorts. One institutional cohort (n = 94) was used to identify the most prognostic features and train a Cox regression model to predict risk of recurrence and death. Survival analysis was used to validate the algorithm as a biomarker of recurrence or death in the remaining 5 cohorts (n = 345). All statistical tests were 2-sided.
RESULTS
OP-TIL separated stage I HPV-associated OPSCC patients with 30 or less pack-year smoking history into low-risk (2-year disease-free survival [DFS] = 94.2%; 5-year DFS = 88.4%) and high-risk (2-year DFS = 82.5%; 5-year DFS = 74.2%) groups (hazard ratio = 2.56, 95% confidence interval = 1.52 to 4.32; P < .001), even after adjusting for age, smoking status, T and N classification, and treatment modality on multivariate analysis for DFS (hazard ratio = 2.27, 95% confidence interval = 1.32 to 3.94; P = .003).
CONCLUSIONS
OP-TIL can identify stage I HPV-associated OPSCC patients likely to be poor candidates for treatment de-escalation. Following validation on previously completed multi-institutional clinical trials, OP-TIL has the potential to be a biomarker, beyond clinical stage and HPV status, that can be used clinically to optimize patient selection for de-escalation.
Identifiants
pubmed: 34850048
pii: 6446037
doi: 10.1093/jnci/djab215
pmc: PMC9002277
doi:
Substances chimiques
Biomarkers
0
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
609-617Subventions
Organisme : NCI NIH HHS
ID : T32 CA094186
Pays : United States
Organisme : NCRR NIH HHS
ID : C06 RR012463
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA125123
Pays : United States
Organisme : BLRD VA
ID : I01 BX004121
Pays : United States
Organisme : NIBIB NIH HHS
ID : R43 EB028736
Pays : United States
Organisme : NCI NIH HHS
ID : U54 CA254566
Pays : United States
Organisme : CSRD VA
ID : IK2 CX001953
Pays : United States
Organisme : NIDCD NIH HHS
ID : T32 DC000027
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press.
Références
Ann Oncol. 2015 Feb;26(2):259-71
pubmed: 25214542
J Bioinform Comput Biol. 2017 Aug;15(4):1750017
pubmed: 28718343
Sci Rep. 2020 Jan 14;10(1):243
pubmed: 31937831
Nat Med. 2020 Jul;26(7):1054-1062
pubmed: 32461698
IEEE Trans Med Imaging. 2020 Nov;39(11):3257-3267
pubmed: 31283474
Arch Pathol Lab Med. 2018 May;142(5):559-597
pubmed: 29251996
Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1125-1131
pubmed: 30513378
J Clin Oncol. 2021 Mar 20;39(9):956-965
pubmed: 33507809
J Mol Diagn. 2020 Jan;22(1):50-59
pubmed: 31843276
Laryngoscope Investig Otolaryngol. 2019 Oct 17;4(6):617-623
pubmed: 31890879
BMC Cancer. 2020 Feb 14;20(1):125
pubmed: 32059705
SLAS Discov. 2017 Mar;22(3):213-237
pubmed: 28231035
J Pathol Inform. 2016 Jul 26;7:29
pubmed: 27563488
Laryngoscope. 2020 Apr;130(4):930-938
pubmed: 31070246
Cancer. 1986 Jul 1;58(1):158-62
pubmed: 3708540
Stat Med. 1997 Feb 28;16(4):385-95
pubmed: 9044528
Eur Arch Otorhinolaryngol. 2013 Sep;270(10):2585-93
pubmed: 23263268
Clin Cancer Res. 2019 Mar 1;25(5):1526-1534
pubmed: 30201760
Nature. 2015 May 28;521(7553):436-44
pubmed: 26017442
Head Neck Pathol. 2020 Sep;14(3):666-688
pubmed: 31741151
Adv Anat Pathol. 2017 Nov;24(6):311-335
pubmed: 28777143
Br J Cancer. 2014 Jan 21;110(2):489-500
pubmed: 24169344
Int J Cancer. 2020 Dec 1;147(11):3236-3249
pubmed: 32478869
J Clin Oncol. 2021 Mar 20;39(9):947-949
pubmed: 33577355
JCI Insight. 2019 Jan 10;4(1):
pubmed: 30626753
MMWR Morb Mortal Wkly Rep. 2016 Jul 08;65(26):661-6
pubmed: 27387669
BMC Cancer. 2020 Sep 23;20(1):912
pubmed: 32967643
Am J Surg Pathol. 2014 Jan;38(1):128-37
pubmed: 24145650
Sci Rep. 2020 Jan 16;10(1):526
pubmed: 31949181
J Med Imaging (Bellingham). 2017 Apr;4(2):021105
pubmed: 28382314
JCO Clin Cancer Inform. 2019 Apr;3:1-7
pubmed: 30990737
Cell Rep. 2018 Apr 3;23(1):181-193.e7
pubmed: 29617659